The Boeing Company (BA) Sees Need On Educating Public On Space Exploration Programs

The Boeing Company (NYSE:BA) is going through a rough ride in the context with its old tie-up with NASA, amid the contracting funding and less focus on space exploration programs. During an interview with CNBC, John Elbon, who is Vice President and General Manager for Space Exploration in The Boeing Company (NYSE:BA), opened up about the shrinking budgets earmarked towards space exploration industry; while he stressed on the importance of creating awareness that the benefits of investing in space programs are immense and result oriented.

The Boeing Company (NYSE:BA)

Elbon stressed that the current allocation of budget to NASA space programs is 0.4% of the total national spent, which is relatively a very small allocation when compared to the benefits that it being delivered. He said that that the returns on space programs delivers incredible results, helping to bring change in how people live on earth. Moreover, a significant research and science that is provided by stations now, particularly related to the health segment that will highly impact the way things turnout on earth.

“There’s a job for us to do of educating the public on, first of all, the small amount that is spent, and secondly, the incredible benefits that come from that, that affect us here on Earth,” said Elbon

In order to bring a clearer picture of how station programs and research are contributing to healthcare benefits, the VP of¬†The Boeing Company (NYSE:BA),¬†pointed out that the recent research in protein crystal growth showed that it had a very significant potential in contributing to the cure of ‘Duchenne Muscular Dystrophy,’ which is a fatal genetic disorder. Further, the subsequent study of its impact is now being carried out in Osaka, Japan, in order to develop a cure and thus, Elbon said that if a treatment comes out then the success in this one area itself will justify and make the amount of the money spent worth.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!